Neuroprotective benefit and safety of preterm neonatal sulfate supplementation
This study will investigate whether sulfate therapy reduces the risk of developing adverse neurodevelopmental outcomes after preterm birth. The study, led by Associate Professor Paul Dawson, has been awarded a grant by the Australian National Health and Medical Research Council (NHMRC). The study is being undertaken following evidence that sulfate is important for brain development and that preterm infants rapidly become sulfate deficient unless their mother receives magnesium sulfate during preterm labour. Magnesium sulfate is currently administered to mothers in preterm labour at less than 30 weeks gestation and reduces the risk of cerebral palsy in the infant. However, almost half of women miss out on this neuroprotective therapy due to insufficient time to give the treatment.
To address these challenges, this NHMRC-funded project will investigate both safety and neuroprotective benefit aspects of neonatal sulphate supplementation using an established and clinically relevant preterm animal model. The study is designed specifically to support direct translation to a clinical trial of sulfate supplementation in very preterm infants.